MiMedX Q2 net sales $99M record, up 13% YoY; raises 2025 growth to low double-digits

MIMEDX GROUP, INC.

2025-Q2 EPS reported $0.11 revenue$186,810,000

Net sales $99M (record), +13% YoY; GAAP net income $10M ($0.06 EPS); prior year included $9.3M settlement benefit.
Adjusted EBITDA $24M (25% margin); cash $119M, up $15M from Dec 2024.
Wound sales +12%, Surgical +15% YoY; driven by new products CELERA, EMERGE, HELIOGEN.
Raises 2025 net sales growth outlook to low double-digits; reaffirms adjusted EBITDA margin above 20%.
CEO supports CMS proposal to overhaul skin substitute reimbursement; engaging in comment period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.